Lipicard 160 Tablet contains Fenofibrate 160 mg, a lipid-modifying agent primarily used to manage hypercholesterolemia and hypertriglyceridemia. Fenofibrate belongs to the fibrate class of medications and acts by activating peroxisome proliferator-activated receptor alpha (PPARα), which leads to increased lipolysis and elimination of triglyceride-rich particles from plasma. This results in a significant reduction in serum triglycerides and low-density lipoprotein cholesterol (LDL-C), along with an increase in high-density lipoprotein cholesterol (HDL-C). Lipicard 160 is indicated for patients with primary hyperlipidemia or mixed dyslipidemia who have not achieved adequate lipid control through diet and lifestyle modifications alone. It is also used to reduce the risk of cardiovascular events in patients with elevated lipid levels. The tablet should be taken orally, usually once daily with food to enhance absorption. Common adverse effects may include gastrointestinal disturbances, elevated liver enzymes, and muscle-related symptoms such as myalgia; therefore, periodic monitoring of liver function tests and creatine kinase levels is recommended during therapy. Lipicard 160 should be used cautiously in patients with renal or hepatic impairment and is contraindicated in those with severe liver disease or gallbladder pathology. It is essential to follow the prescribed dosage and consult a healthcare professional before initiating therapy.